244 related articles for article (PubMed ID: 25346146)
1. Incidence and risk factors for cytomegalovirus (CMV) reactivation following autologous hematopoietic stem cell transplantation in children.
Hussein AA; Al-Antary ET; Najjar R; Al-Hamdan DS; Al-Zaben A; Frangoul H
Pediatr Blood Cancer; 2015 Jun; 62(6):1099-101. PubMed ID: 25346146
[TBL] [Abstract][Full Text] [Related]
2. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
Almyroudis NG; Jakubowski A; Jaffe D; Sepkowitz K; Pamer E; O'Reilly RJ; Papanicolaou GA
Transpl Infect Dis; 2007 Dec; 9(4):286-94. PubMed ID: 17511819
[TBL] [Abstract][Full Text] [Related]
3. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus reactivation following hematopoietic stem cell transplantation.
Sharma SK; Kumar S; Agrawal N; Singh L; Mukherjee A; Seth T; Mishra P; Mathur S; Dar L; Mahapatra M
J Infect Dev Ctries; 2013 Dec; 7(12):1003-7. PubMed ID: 24334950
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus (CMV) infections in children undergoing hematopoetic stem cell transplantation.
Zaucha-Prazmo A; Wójcik B; Drabko K; Choma M; Kowalczyk JR
Pediatr Hematol Oncol; 2005 Jun; 22(4):271-6. PubMed ID: 16020113
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus infection in children undergoing hematopoietic stem cell transplantation in Chile.
Paris C; Kopp K; King A; Santolaya ME; Zepeda AJ; Palma J
Pediatr Blood Cancer; 2009 Sep; 53(3):453-8. PubMed ID: 19418548
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus viremia, viruria and disease after autologous peripheral blood stem cell transplantation: no need for surveillance.
Bilgrami S; Aslanzadeh J; Feingold JM; Bona RD; Clive J; Dorsky D; Edwards RL; Tutschka PJ
Bone Marrow Transplant; 1999 Jul; 24(1):69-73. PubMed ID: 10435738
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation.
Massoud R; Assi R; Fares E; Haffar B; Charafeddine M; Kreidieh N; Mahfouz R; Kanj SS; El Zakhem A; Kharfan-Dabaja M; Bazarbachi A; El Cheikh J
J Clin Virol; 2017 Oct; 95():36-41. PubMed ID: 28843110
[TBL] [Abstract][Full Text] [Related]
9. Early cytomegalovirus reactivation leaves a specific and dynamic imprint on the reconstituting T cell compartment long-term after hematopoietic stem cell transplantation.
Lugthart G; van Ostaijen-Ten Dam MM; Jol-van der Zijde CM; van Holten TC; Kester MG; Heemskerk MH; Bredius RG; van Tol MJ; Lankester AC
Biol Blood Marrow Transplant; 2014 May; 20(5):655-61. PubMed ID: 24462981
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus infection in children who underwent hematopoietic stem cell transplantation at a single center: a retrospective study of the risk factors.
Yoon HS; Lee JH; Choi ES; Seo JJ; Moon HN; Kim MN; Im HJ
Pediatr Transplant; 2009 Nov; 13(7):898-905. PubMed ID: 19032414
[TBL] [Abstract][Full Text] [Related]
11. High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation.
Hazar V; Kansoy S; Küpesiz A; Aksoylar S; Kantar M; Yeşilipek A
Bone Marrow Transplant; 2004 May; 33(9):931-5. PubMed ID: 15034541
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus infection in autologous stem cell transplant recipients in the era of rituximab.
Jain T; John J; Kotecha A; Deol A; Saliminia T; Revankar S; Chandrasekar P
Ann Hematol; 2016 Aug; 95(8):1323-7. PubMed ID: 27225264
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment.
Hazar V; Ugur A; Colak D; Saba R; Tezcan G; Kupesiz A; Karadogan I; Gultekin M; Yesilipek A; Undar L
Jpn J Infect Dis; 2006 Aug; 59(4):216-21. PubMed ID: 16936338
[TBL] [Abstract][Full Text] [Related]
14. [Cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and related risk factors].
Huang XJ; Xu LP; Ren HY; Zhang YC; Guo NL; Lu DP
Zhonghua Yi Xue Za Zhi; 2003 May; 83(9):766-9. PubMed ID: 12899755
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus.
Liu YC; Lu PL; Hsiao HH; Chang CS; Liu TC; Yang WC; Lin SF
Ann Hematol; 2012 Apr; 91(4):587-95. PubMed ID: 21997849
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation.
Kim JH; Goulston C; Sanders S; Lampas M; Zangari M; Tricot G; Hanson KE
Biol Blood Marrow Transplant; 2012 Nov; 18(11):1753-8. PubMed ID: 22728249
[TBL] [Abstract][Full Text] [Related]
17. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease.
Bordon V; Bravo S; Van Renterghem L; de Moerloose B; Benoit Y; Laureys G; Dhooge C
Transpl Infect Dis; 2008 Feb; 10(1):19-23. PubMed ID: 17511814
[TBL] [Abstract][Full Text] [Related]
18. Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Leukemia.
Inagaki J; Noguchi M; Kurauchi K; Tanioka S; Fukano R; Okamura J
Biol Blood Marrow Transplant; 2016 Feb; 22(2):300-306. PubMed ID: 26371373
[TBL] [Abstract][Full Text] [Related]
19. Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure.
Nakamura R; Battiwalla M; Solomon S; Follmann D; Chakrabarti S; Cortez K; Hensel N; Childs R; Barrett AJ
Biol Blood Marrow Transplant; 2004 Jan; 10(1):49-57. PubMed ID: 14752779
[TBL] [Abstract][Full Text] [Related]
20. Oral Valganciclovir as Preemptive Therapy for Cytomegalovirus Reactivation in Pediatric Hematopoietic Stem Cell Transplant Patients.
Atay D; Erbey F; Akcay A; Dag A; Ozturk G
J Pediatr Hematol Oncol; 2015 Oct; 37(7):543-7. PubMed ID: 26207778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]